148 related articles for article (PubMed ID: 35189719)
1. Association of polymorphisms in
Ozberk D; Haywood A; Sutherland HG; Yu C; Albury CL; Zunk M; George R; Good P; Griffiths LR; Hardy J; Haupt LM
Pharmacogenomics; 2022 Apr; 23(5):281-289. PubMed ID: 35189719
[No Abstract] [Full Text] [Related]
2. Impact of SNP-SNP interaction among ABCB1, ARRB2, DRD1 and OPRD1 on methadone dosage requirement in Han Chinese patients.
Luo R; Li X; Qin S; Luo Z; Luo X; Hu P; Liu Z; Feng X; Li X
Pharmacogenomics; 2017 Dec; 18(18):1659-1670. PubMed ID: 29173032
[TBL] [Abstract][Full Text] [Related]
3. Genetic Factors Associated With Pain Severity, Daily Opioid Dose Requirement, and Pain Response Among Advanced Cancer Patients Receiving Supportive Care.
Yennurajalingam S; Astolfi A; Indio V; Beccaro M; Schipani A; Yu R; Shete S; Reyes-Gibby C; Lu Z; Williams JL; Yeun SC; Anderson AE; Biasco G; Bruera E
J Pain Symptom Manage; 2021 Oct; 62(4):785-795. PubMed ID: 33848569
[TBL] [Abstract][Full Text] [Related]
4. β-Arrestin2 influences the response to methadone in opioid-dependent patients.
Oneda B; Crettol S; Bochud M; Besson J; Croquette-Krokar M; Hämmig R; Monnat M; Preisig M; Eap CB
Pharmacogenomics J; 2011 Aug; 11(4):258-66. PubMed ID: 20514076
[TBL] [Abstract][Full Text] [Related]
5. [Association between β-arrestin2 genetic polymorphism and response to methadone maintenance treatment in heroin-dependent patients in Han population in Hunan province].
Luo R; Feng XL; Luo X; Liu ZS; Hu PW; Liu S; Li XL
Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Jun; 37(6):872-5. PubMed ID: 27346119
[TBL] [Abstract][Full Text] [Related]
6. β-Arrestin 2 (ARRB2) Polymorphism is Associated With Adverse Consequences of Chronic Heroin Use.
Karavidha KK; Burmeister M; Greenwald MK
Am J Addict; 2021 Jul; 30(4):351-357. PubMed ID: 33783060
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Methadone as a Second-Line Opioid for Cancer Pain in an Outpatient Clinic: A Prospective Open-Label Study.
Porta-Sales J; Garzón-Rodríguez C; Villavicencio-Chávez C; Llorens-Torromé S; González-Barboteo J
Oncologist; 2016 Aug; 21(8):981-7. PubMed ID: 27306912
[TBL] [Abstract][Full Text] [Related]
8. The association of β-arrestin2 polymorphisms with response to antidepressant treatment in depressed patients.
Petit AC; El Asmar K; David DJ; Gardier AM; Becquemont L; Fève B; Verstuyft C; Corruble E
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():74-79. PubMed ID: 29031912
[TBL] [Abstract][Full Text] [Related]
9. Advanced cancer pain: the search for genetic factors correlated with interindividual variability in opioid requirement.
Matic M; Jongen JL; Elens L; de Wildt SN; Tibboel D; Sillevis Smitt PA; van Schaik RH
Pharmacogenomics; 2017 Aug; 18(12):1133-1142. PubMed ID: 28745577
[TBL] [Abstract][Full Text] [Related]
10. Association of KCNJ6 rs2070995 and methadone response for pain management in advanced cancer at end-of-life.
Ozberk D; Haywood A; Sutherland HG; Yu C; Albury CL; Zunk M; George R; Good P; Griffiths LR; Hardy J; Haupt LM
Sci Rep; 2022 Oct; 12(1):17422. PubMed ID: 36261449
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of Methadone for Pain Management in Palliative Care.
Irwin MN; Ellingrod VL; Smith MA
J Pain Symptom Manage; 2022 Jan; 63(1):e142-e145. PubMed ID: 34461232
[No Abstract] [Full Text] [Related]
12. Methadone as first-line opioid treatment for cancer pain in a developing country palliative care unit.
Peirano GP; Mammana GP; Bertolino MS; Pastrana T; Vega GF; Russo J; Varela G; Vignaroli E; Ruggiero R; Armesto A; Camerano G; Dran G
Support Care Cancer; 2016 Aug; 24(8):3551-6. PubMed ID: 27022964
[TBL] [Abstract][Full Text] [Related]
13. Single-Nucleotide Polymorphisms in TAOK3 Are Associated With High Opioid Requirement for Pain Management in Patients With Advanced Cancer Admitted to a Tertiary Palliative Care Unit.
Gutteridge T; Kumaran M; Ghosh S; Fainsinger R; Klepstad P; Tarumi Y; Damaraju S; Baracos VE
J Pain Symptom Manage; 2018 Oct; 56(4):560-566. PubMed ID: 30031856
[TBL] [Abstract][Full Text] [Related]
14. Methadone as a First-Line Opioid in Cancer Pain Management: A Systematic Review.
Mercadante S; Bruera E
J Pain Symptom Manage; 2018 Mar; 55(3):998-1003. PubMed ID: 29101087
[TBL] [Abstract][Full Text] [Related]
15. Improved Pain Control in Terminally Ill Cancer Patients by Introducing Low-Dose Oral Methadone in Addition to Ongoing Opioid Treatment.
Fürst P; Lundström S; Klepstad P; Runesdotter S; Strang P
J Palliat Med; 2018 Feb; 21(2):177-181. PubMed ID: 28792784
[TBL] [Abstract][Full Text] [Related]
16. The role of methadone in cancer-induced bone pain: a retrospective cohort study.
Sulistio M; Wojnar R; Key S; Kwok J; Al-Rubaie Z; Michael N
Support Care Cancer; 2021 Mar; 29(3):1327-1335. PubMed ID: 32627056
[TBL] [Abstract][Full Text] [Related]
17. Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study).
Matsuoka H; Tsurutani J; Chiba Y; Fujita Y; Terashima M; Yoshida T; Sakai K; Otake Y; Koyama A; Nishio K; Nakagawa K
BMC Cancer; 2017 Oct; 17(1):674. PubMed ID: 28985716
[TBL] [Abstract][Full Text] [Related]
18. Methadone as First-line Opioid for the Management of Cancer Pain.
Mercadante S; Adile C; Ferrera P; Pallotti MC; Ricci M; Bonanno G; Casuccio A
Oncologist; 2022 Apr; 27(4):323-327. PubMed ID: 35380722
[TBL] [Abstract][Full Text] [Related]
19. Pain polymorphisms and opioids: An evidence based review.
Vieira CMP; Fragoso RM; Pereira D; Medeiros R
Mol Med Rep; 2019 Mar; 19(3):1423-1434. PubMed ID: 30592275
[TBL] [Abstract][Full Text] [Related]
20. Association study of the β-arrestin 2 gene (ARRB2) with opioid and cocaine dependence in a European-American population.
Ambrose-Lanci LM; Vaswani M; Clarke TK; Zeng A; Lohoff FW; Ferraro TN; Berrettini WH
Psychiatr Genet; 2012 Jun; 22(3):141-5. PubMed ID: 22472784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
